108 filings
Page 4 of 6
6-K
5daqv
10 Dec 20
Current report (foreign)
6:22am
6-K/A
uy6qix8 n5xa4ws4
13 Nov 20
Aslan Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
6:03am
6-K
0ysge1lvf wtc6l
9 Nov 20
Aslan Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
9:00am
6-K
iyva9cob
9 Oct 20
Current report (foreign)
4:03pm
6-K
5ub3jlgruz1r
22 Sep 20
Aslan Pharmaceuticals Completes Enrolment In Second Cohort and Opens New Sites In Us and Australia In ASLAN004 Atopic Dermatitis Study
12:00am
6-K
grx j7a0si
17 Sep 20
Current report (foreign)
5:02pm
6-K
r3rxmd3
4 Sep 20
Current report (foreign)
10:14am
6-K
hhlke2u
24 Aug 20
Aslan Pharmaceuticals Resumes Recruitment of New Patients into ASLAN004 Study
9:25am
6-K
4lq4gu9r39p691
3 Aug 20
Aslan Pharmaceuticals Appoints Kenneth Kobayashi, MD, As Chief Medical Officer
6:24am
6-K
apnkz73rdi f46
17 Jul 20
Aslan Pharmaceuticals Announces the Move of Its Primary Listing to Nasdaq and Delisting from Taipei Exchange
6:03am
6-K
ov74vm0bhrat
13 Jul 20
Aslan Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
12:30pm
6-K
91qm40d8u 80kwgy1k
15 Jun 20
Current report (foreign)
6:04am
6-K
rslzj9xp7hw
9 Jun 20
Current report (foreign)
4:31pm
6-K
lh2ib99u
11 May 20
Aslan Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
9:37pm
6-K
0d05acrxaeugunwd0
5 May 20
Current report (foreign)
6:02am
6-K
325tuamt jj
13 Apr 20
Aslan Pharmaceuticals Temporarily Pauses Recruitment of New Patients into ASLAN004 Study Due to COVID-19
10:14am
6-K
7x0sq 2kpr6b
23 Mar 20
Current report (foreign)
6:02am
6-K
gfglh33hrq zt
19 Mar 20
Aslan Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
6:02am
6-K
vh0p 2qzt
19 Mar 20
Current report (foreign)
6:02am
6-K
b0rkwkcp 1op4art
7 Jan 20
Current report (foreign)
7:56am